EyePoint Pharmaceuticals Reports Q4 and Full-Year 2025 Financial Results

Pivotal DURAVYU Phase 3 Programs Advance in Wet AMD and DME

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) has released its financial results for the fourth quarter and full-year ended December 31, 2025, alongside major corporate and R&D updates that could significantly impact the company’s valuation and future share performance.

Key Highlights

• Both pivotal Phase 3 trials for DURAVYU in wet Age-Related Macular Degeneration (AMD) are on track for topline data readouts beginning mid-2026.
• First patients dosed in COMO and CAPRI pivotal Phase 3 trials for Diabetic Macular Edema (DME), positioning DURAVYU as the only tyrosine kinase inhibitor (TKI) in development for DME.
• Michael Campbell appointed as Chief Commercial Officer to lead DURAVYU’s commercial strategy and launch readiness.
• Strong balance sheet with over \$300 million in cash and investments as of December 31, 2025, extending runway into Q4 2027.
• Expansion of intellectual property protection for DURAVYU, with a new U.S. patent issued in February 2026, extending coverage into 2043.
• Completion of registration batches for DURAVYU at the Northbridge, Massachusetts commercial facility to support pending NDA filing.
• Gross proceeds of \$172.5 million raised via a public offering in October 2025.

Clinical Development and Regulatory Updates

DURAVYU in Wet AMD

• The LUGANO Phase 3 trial topline data is expected mid-2026, with the LUCIA trial data anticipated shortly thereafter. Both trials are identical, enrolling over 900 patients and employing a non-inferiority design versus on-label aflibercept, with six-month re-dosing intervals.
• The independent Data Safety Monitoring Committee (DSMC) has recommended the continuation of the trials without protocol modifications, following its second scheduled review.
• As of September 29, 2025, interim masked safety data showed a safety profile consistent with previous favorable findings for DURAVYU.

DURAVYU in DME

• First patients have been dosed in the pivotal Phase 3 COMO and CAPRI trials for DME, with rapid enrollment of 240 patients each expected. Topline results are anticipated in H2 2027.
• Phase 3 program design is aligned with both the FDA and EMA, following a non-inferiority pathway with aflibercept as the control and DURAVYU re-dosing every six months.

Scientific and Clinical Data Presentations

• Preclinical data suggest DURAVYU could be the only TKI with a novel, multi-mechanism of action (MOA), inhibiting VEGF, PDGF, and pro-inflammatory IL-6 signaling, with no TIE-2 inhibition.
• DURAVYU demonstrated more than 50% reduction in IL-6 activity, possibly delivering synergistic anti-inflammatory effects in addition to VEGF inhibition for wet AMD and DME.
• Clinical updates and post hoc analyses were presented at leading ophthalmology conferences, further highlighting the drug’s durability and early improvements in vision and anatomy.

Financial Results

Fourth Quarter 2025

• Total net revenue: \$0.6 million (vs. \$11.6 million in Q4 2024).
• Net product revenue: \$0.3 million (vs. \$0.8 million in Q4 2024).
• License and royalty revenue: \$0.3 million (vs. \$10.8 million in Q4 2024), mainly due to recognition of deferred revenue from the 2023 YUTIQ product rights agreement.
• Operating expenses: \$71.0 million (up from \$56.8 million), reflecting increased R&D for Phase 3 DURAVYU trials.
• Net loss: \$67.6 million, or \$(0.81) per share (vs. \$41.4 million, or \$(0.64) per share in Q4 2024).
• Weighted average common shares outstanding: 83 million (up from 64.6 million).

Full Year 2025

• Total net revenue: \$31.4 million (vs. \$43.3 million in 2024).
• Net product revenue: \$1.6 million (vs. \$3.2 million).
• License and royalty revenue: \$29.8 million (vs. \$40.1 million).
• Operating expenses: \$274.8 million (up from \$189.1 million), primarily due to increased R&D for DURAVYU.
• Net loss: \$232.0 million, or \$(3.17) per share (vs. \$130.9 million, or \$(2.32) per share in 2024).
• Cash and investments: \$306 million at year-end 2025 (vs. \$371 million at year-end 2024).

Financial Outlook

• Current cash, cash equivalents, and investments are expected to fund operations into Q4 2027, supporting key Phase 3 milestones in wet AMD (2026) and fully funding pivotal DME trials.

Corporate and Strategic Updates

• Leadership: Michael Campbell’s appointment as Chief Commercial Officer provides seasoned leadership for DURAVYU’s anticipated commercial launch.
• Intellectual Property: A newly issued U.S. patent for the DURAVYU insert formulation extends market exclusivity into 2043.
• Manufacturing: Registration batches for DURAVYU have been completed at the company’s commercial facility, supporting the Chemistry, Manufacturing, and Controls (CMC) section of the upcoming NDA filing.
• Capital Raising: The company completed a \$172.5 million underwritten public offering in October 2025, bolstering its cash position.

Potential Share Price Catalysts and Risks

• Upcoming topline data from the pivotal Phase 3 LUGANO and LUCIA trials in wet AMD (mid-2026) represent a significant value inflection point. Positive results could position DURAVYU as the first-to-market sustained delivery TKI for major retinal diseases.
• First-in-class status in DME and the drug’s multi-MOA and safety profile could enhance commercial prospects and market penetration.
• Completion of pivotal trials and NDA submission for DURAVYU are key regulatory and commercial milestones that may drive share price movement.
• Potential risks include regulatory delays, unexpected safety or efficacy findings, and the need for additional capital if timelines shift.
• Ongoing litigation, regulatory correspondence (including an FDA warning letter for the Watertown, MA facility), and macroeconomic factors remain important considerations.

Conference Call Details

EyePoint will host a conference call today at 8:30 a.m. ET to discuss the results and recent developments. The webcast will be available on the company’s investor relations website.

About EyePoint Pharmaceuticals

EyePoint is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with a strong history of drug development and market launches in ophthalmology. DURAVYU (EYP-1901) is the company’s lead candidate, licensed from Equinox Sciences for use outside China, Macao, Hong Kong, and Taiwan. FDA approval for DURAVYU is pending, and timelines may change.

Disclaimer

This article contains information based on EyePoint Pharmaceuticals’ public filings and press releases. Forward-looking statements reflect management’s expectations but are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review all relevant filings and consult financial advisors before making investment decisions. This article is not investment advice.

View EyePoint, Inc. Historical chart here